• Eurofarma’s board met Aug. 25, 2026 to overhaul governance policies, committee structure, and key committee appointments.
• Directors accepted the resignation of independent board member Cláudio Roberto Ely, effective upon receipt of his letter.
• A corporate compensation policy for governance bodies was adopted, effective immediately.
• Board committees were reorganized, including creation of Strategy, Investments and Innovation Committee plus a Commercial Committee.
• Committee memberships were elected or refreshed through April 30, 2028, alongside related internal rules and policy updates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eurofarma Laboratorios SA published the original content used to generate this news brief on August 25, 2026, and is solely responsible for the information contained therein.